Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic Hepatitis Delta Virus (HDV) Infection: Overview
Chronic Hepatitis Delta Virus (HDV) Infection is caused by hepatitis D virus with simultaneous presence of hepatitis B infection. HDV-HBV co-infection is the most severe form of chronic infection leading liver-related death and hepatocellular carcinomas. The virus can transmit from person to person and affect nearly 5% of population with prior HBV infection.
“Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape is provided which includes the disease overview and Chronic Hepatitis Delta Virus (HDV) Infection treatment guidelines. The assessment part of the report embraces, in depth Chronic Hepatitis Delta Virus (HDV) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis Delta Virus (HDV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis Delta Virus (HDV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis Delta Virus (HDV) Infection.
Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs Chapters
This segment of the Chronic Hepatitis Delta Virus (HDV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs
Lonafarnib: Eiger Biopharmaceuticals
Eiger’s lead drug candidate, Lonafarnib is an orally administered small molecule in development for the treatment of chronic HDV infection. The Phase I and II clinical trials have demonstrated good safety and efficacy. The drug acts by blocking the key enzyme required by HDV virus to replicate which is anticipated to cure the HDV infection.
JNJ-73763989: Janssen Pharmaceuticals
Janssen “breakthrough” drug JNJ-73763989 is currently being evaluated for the treatment of chronic hepatitis delta virus infection. The drug is a liver-targeted antiviral class molecule designed to treat HVB and HVD infection via RNA interference mechanism.
Further product details are provided in the report……..
Chronic Hepatitis Delta Virus (HDV) Infection: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Hepatitis Delta Virus (HDV) Infection drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic Hepatitis Delta Virus (HDV) Infection
There are approx. 5+ key companies which are developing the therapies for Chronic Hepatitis Delta Virus (HDV) Infection. The companies which have their Chronic Hepatitis Delta Virus (HDV) Infection drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Janssen Pharmaceuticals and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Chronic Hepatitis Delta Virus (HDV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Hepatitis Delta Virus (HDV) Infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis Delta Virus (HDV) Infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis Delta Virus (HDV) Infection drugs.
Chronic Hepatitis Delta Virus (HDV) Infection Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Hepatitis Delta Virus (HDV) Infection: Overview
Chronic Hepatitis Delta Virus (HDV) Infection is caused by hepatitis D virus with simultaneous presence of hepatitis B infection. HDV-HBV co-infection is the most severe form of chronic infection leading liver-related death and hepatocellular carcinomas. The virus can transmit from person to person and affect nearly 5% of population with prior HBV infection.
“Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Hepatitis Delta Virus (HDV) Infection pipeline landscape is provided which includes the disease overview and Chronic Hepatitis Delta Virus (HDV) Infection treatment guidelines. The assessment part of the report embraces, in depth Chronic Hepatitis Delta Virus (HDV) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis Delta Virus (HDV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis Delta Virus (HDV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis Delta Virus (HDV) Infection.
Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs Chapters
This segment of the Chronic Hepatitis Delta Virus (HDV) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Hepatitis Delta Virus (HDV) Infection Emerging Drugs
Lonafarnib: Eiger Biopharmaceuticals
Eiger’s lead drug candidate, Lonafarnib is an orally administered small molecule in development for the treatment of chronic HDV infection. The Phase I and II clinical trials have demonstrated good safety and efficacy. The drug acts by blocking the key enzyme required by HDV virus to replicate which is anticipated to cure the HDV infection.
JNJ-73763989: Janssen Pharmaceuticals
Janssen “breakthrough” drug JNJ-73763989 is currently being evaluated for the treatment of chronic hepatitis delta virus infection. The drug is a liver-targeted antiviral class molecule designed to treat HVB and HVD infection via RNA interference mechanism.
Further product details are provided in the report……..
Chronic Hepatitis Delta Virus (HDV) Infection: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Hepatitis Delta Virus (HDV) Infection drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic Hepatitis Delta Virus (HDV) Infection
There are approx. 5+ key companies which are developing the therapies for Chronic Hepatitis Delta Virus (HDV) Infection. The companies which have their Chronic Hepatitis Delta Virus (HDV) Infection drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Janssen Pharmaceuticals and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Chronic Hepatitis Delta Virus (HDV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Hepatitis Delta Virus (HDV) Infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis Delta Virus (HDV) Infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis Delta Virus (HDV) Infection drugs.
Chronic Hepatitis Delta Virus (HDV) Infection Report Insights
- Chronic Hepatitis Delta Virus (HDV) Infection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Hepatitis Delta Virus (HDV) Infection drugs?
- How many Chronic Hepatitis Delta Virus (HDV) Infection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Hepatitis Delta Virus (HDV) Infection?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Hepatitis Delta Virus (HDV) Infection therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Hepatitis Delta Virus (HDV) Infection and their status?
- What are the key designations that have been granted to the emerging drugs?
- Janssen Pharmaceuticals
- Eiger Biopharmaceutical
- Pharma Essentia
- JNJ-73763989
- Lonafarinib
- P1101
Introduction
Executive Summary
Chronic Hepatitis Delta Virus (HDV) Infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Hepatitis Delta Virus (HDV) Infection – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chronic Hepatitis Delta Virus (HDV) Infection companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chronic Hepatitis Delta Virus (HDV) Infection Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Lonafarnib: Eiger Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
JNJ-73763989: Janssen Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Hepatitis Delta Virus (HDV) Infection Key Companies
Chronic Hepatitis Delta Virus (HDV) Infection Key Products
Chronic Hepatitis Delta Virus (HDV) Infection- Unmet Needs
Chronic Hepatitis Delta Virus (HDV) Infection- Market Drivers and Barriers
Chronic Hepatitis Delta Virus (HDV) Infection- Future Perspectives and Conclusion
Chronic Hepatitis Delta Virus (HDV) Infection Analyst Views
Chronic Hepatitis Delta Virus (HDV) Infection Key Companies
Appendix
Executive Summary
Chronic Hepatitis Delta Virus (HDV) Infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic Hepatitis Delta Virus (HDV) Infection – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chronic Hepatitis Delta Virus (HDV) Infection companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chronic Hepatitis Delta Virus (HDV) Infection Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Lonafarnib: Eiger Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
JNJ-73763989: Janssen Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Hepatitis Delta Virus (HDV) Infection Key Companies
Chronic Hepatitis Delta Virus (HDV) Infection Key Products
Chronic Hepatitis Delta Virus (HDV) Infection- Unmet Needs
Chronic Hepatitis Delta Virus (HDV) Infection- Market Drivers and Barriers
Chronic Hepatitis Delta Virus (HDV) Infection- Future Perspectives and Conclusion
Chronic Hepatitis Delta Virus (HDV) Infection Analyst Views
Chronic Hepatitis Delta Virus (HDV) Infection Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic Hepatitis Delta Virus (HDV) Infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic Hepatitis Delta Virus (HDV) Infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic Hepatitis Delta Virus (HDV) Infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic Hepatitis Delta Virus (HDV) Infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
